Aptuit Appoints New CEO - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Aptuit Appoints New CEO

Untitled Document

Aptuit, a provider of outsourced services in the early development space, has appointed Jonathan Goldman, MD, as the company’s new CEO. Goldman joins the company after working at ICON Clinical Research.

Goldman was most recently executive vice president, global strategic and business development at ICON and a member of the senior leadership team. Previously, his roles at ICON included executive VP, operations, strategic programs and chief medical officer, ICON Medical Imaging.

Before joining ICON, Goldman served for seven years as the chief medical officer of POINT Biomedical, a US-based biopharmaceutical company that discovered and developed microsphere technologies and drugs. In addition, he has held academic positions at the University of California since 2000, most recently as associate clinical professor of medicine in the Division of Cardiology.

Source: Aptuit


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here